Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342513 | 0.71 | RET (0.43) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL342879 | 0.71 | TYRO3 (0.44) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL5705721 | 0.71 | XDH (0.34) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL2273858 | 0.71 | NOS1 (0.38) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL3181459 | 0.71 | PDK2 (0.38) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL29616969 | 0.71 | RET (0.43) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL30440659 | 0.69 | RET (0.42) | XDHRETPI4KALRRK2PI4K2B | |
| Oxypurinol SCHEMBL49280 | 0.68 | SMN1; SMN2 (0.38) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL23186713 | 0.67 | PDPK1 (0.32) | XDHRETPI4KALRRK2PI4K2B | |
| Oxypurinol SCHEMBL8905886 | 0.67 | SMN1; SMN2 (0.37) | XDHRETPI4KALRRK2PI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6037344-A | COMPRISING A PURINE SELECTED FROM THE GROUP CONSISTING OF XANTHINE, HYPOXANTHINE, GUANINE AND MIXTURES THEREOF, AND A XANTHINE OXIDASE INHIBITOR SELECTED FROM THE GROUP CONSISTING OF ALLOPURINOL, OXYPURINOL, MERCAPTO-ALLOPURINOL, | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2000-03-14 | — | — | US | claimed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | XDH 585/4885RET 4104/4885PI4KA 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.